How can pharmaceutical, MedTech, and life sciences companies structure global operations capable of supporting sustainable international growth, regulatory consistency, and successful market integration?

Global expansion is no longer only a commercial opportunity. For companies operating in highly regulated sectors, entering and integrating international markets requires strategic coordination between regulatory affairs, quality systems, supply chain management, local partnerships, risk governance, and operational execution.

In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, explores the strategic role of Global Operations Management and the practical approaches companies should consider when expanding across different jurisdictions. The discussion examines how organizations can move from fragmented international activity to structured, resilient, and coherent global operations.

You will gain a clearer understanding of:

• How global operations management supports international expansion in regulated healthcare sectors;
• Why regulatory alignment and local adaptation must work together when entering new markets;
• How supply chain visibility, traceability, and operational coordination reduce disruption and improve resilience;
• Why risk management, scenario planning, and diversified sourcing are essential in multinational operations;
• How harmonization frameworks, quality systems, local partners, and advisory support can help companies integrate markets more effectively.

For pharmaceutical, MedTech, healthcare, cosmetics, food, and other life sciences companies, internationalization requires more than identifying market potential. It requires the ability to connect strategy, compliance, quality, logistics, and execution into one coherent operational model.

When global operations are poorly structured, companies may face regulatory setbacks, supply chain disruption, increased costs, inconsistent quality, delayed market access, and loss of competitiveness. When they are properly designed, global complexity can become a source of resilience, operational predictability, and sustainable growth.

Tune in to understand how practical Global Operations Management strategies can help companies integrate international markets, strengthen cross-border execution, and build scalable operations capable of supporting long-term success.

Learn more at: https://www.els-solutions.com/

This episode was recorded in 2026. Some information discussed may have been updated since the recording. The podcast was developed based on multiple bibliographic sources. The views expressed reflect the professional experience of ELS members and the referenced materials consulted.

#ELS #ELSGroup hashtag#Podcast #InternationalPharmaTalks #GlobalOperations #OperationsManagement #InternationalMarkets #MarketEntry #InternationalExpansion hashtag#Pharma #MedTech hashtag#LifeSciences #Healthcare #RegulatoryAffairs #SupplyChain hashtag#RiskManagement #Compliance hashtag#BusinessStrategy

How can pharmaceutical and MedTech companies protect their products, data, systems, and patients in an environment where cyber threats are becoming more frequent, more sophisticated, and more operationally disruptive?

Cybersecurity is no longer just an IT concern. In the pharmaceutical and medical technology industries, it has become a strategic and regulatory priority that directly affects product integrity, business continuity, patient safety, data protection, and market trust. In highly interconnected environments shaped by digital health platforms, connected medical devices, cloud-based quality systems, manufacturing automation, and global third-party networks, weaknesses in cybersecurity can result in data breaches, production interruptions, regulatory exposure, product vulnerabilities, financial loss, and lasting reputational harm.

In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, provides an in-depth analysis of the growing role of cybersecurity across the pharmaceutical and MedTech sectors. The discussion explores how cybersecurity is no longer limited to technical infrastructure, but must be embedded into governance, regulatory strategy, risk management, supplier oversight, and lifecycle product compliance.

You will gain a clearer understanding of:

• How cybersecurity failures can directly impact patient safety, product performance, and regulatory compliance;
• Why digital health systems, connected devices, and automated environments create new categories of operational and legal risk;
• The importance of integrating cybersecurity into quality systems, supplier management, and lifecycle governance;

• Why cybersecurity readiness is becoming essential for market access, regulatory credibility, and long-term business sustainability.

In industries where products, systems, and data are closely linked to human health, cybersecurity incidents are not merely technical events, they can become regulatory, financial, clinical, and ethical problems. As digitalization continues to expand across pharmaceutical and MedTech operations, companies must ensure that innovation is supported by strong cybersecurity governance, clear accountability, and resilient control structures.

Tune in to understand how effective cybersecurity strategies can help pharmaceutical and MedTech companies protect critical operations, maintain compliance, secure patient and business data, and strengthen trust in an increasingly digital and highly regulated global market.

Learn more at: https://www.els-solutions.com/

This episode was recorded in 2026. Some information discussed may have been updated since the recording. The podcast was developed based on multiple bibliographic sources. The views expressed reflect the professional experience of ELS members and the referenced materials consulted.

How can companies structure a compliant, efficient, and sustainable distribution model for medical devices in increasingly complex and highly regulated markets?

Medical device distribution is no longer a purely logistical function. It has become a strategic pillar that directly impacts patient safety, regulatory compliance, market access, and brand reputation. In global supply chains marked by multiple intermediaries, cross-border transactions, and evolving regulatory frameworks, weaknesses in documentation, traceability, quality systems, or local representation can lead to delays, product seizures, recalls, financial losses, and long-term reputational damage.

In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, provides an in-depth analysis of the critical elements required to build a successful medical device distribution strategy. The discussion highlights how regulatory alignment, quality governance, and structured partner selection are decisive factors in ensuring both commercial performance and patient protection.

By exploring the intersection between regulatory compliance, importation requirements, local representation, and post-market surveillance obligations, the episode demonstrates how fragmented or poorly structured distribution models increase exposure to inspections, sanctions, and operational disruption. Conversely, robust governance frameworks, qualified distributors, and clear contractual responsibilities reduce risk and enhance market credibility.

You will gain a clearer understanding of:

• How distribution structures directly influence patient safety and product compliance;

• The importance of registrations, licenses, and local regulatory representation in maintaining lawful market presence;

• How gaps in traceability, documentation, and quality oversight can compromise entire supply chains;

• Why due diligence in distributor qualification is essential for long-term sustainability;

• How companies, including small and mid-sized manufacturers, can implement efficient, compliant distribution models without sacrificing competitiveness.

In a sector where medical devices directly affect diagnosis, treatment, and quality of life, distribution failures are not merely operational setbacks, they represent regulatory, financial, and ethical risks. Successful market expansion requires transparent supply chains, clear allocation of responsibilities, and strict adherence to applicable regulatory frameworks.

Tune in to understand how structured regulatory strategies, aligned quality systems, and carefully designed distribution networks can protect patients, preserve brand integrity, and strengthen long-term positioning in the global medical device market.

Learn more at: els-solutions.com

This episode was recorded in 2026. Some information discussed may have been updated since the recording. The podcast was developed based on multiple bibliographic sources. The views expressed reflect the professional experience of ELS members and the referenced materials consulted.

Como a Falsificação de Bebidas e Alimentos Afeta a Saúde Pública, a Conformidade Regulatória e a Sustentabilidade das Marcas?

A falsificação de bebidas e alimentos deixou de ser um problema pontual para se tornar um risco sistêmico, com impactos diretos na saúde pública, na confiança do consumidor e na credibilidade das empresas. Em cadeias de suprimento globais cada vez mais fragmentadas, falhas nos controles regulatórios, na rastreabilidade e na logística criam oportunidades para a inserção de produtos adulterados, ilegais ou de origem desconhecida no mercado formal.

Neste episódio do International Pharma Talks, Eliane Miyazaki, Senior Business Development Manager do ELS Group, analisa de forma aprofundada como a falsificação de alimentos e bebidas está diretamente relacionada a deficiências nos sistemas de controle e fiscalização, e como proteger consumidores e marcas.

Ao explorar o papel da conformidade regulatória e dos sistemas de qualidade ao longo de toda a cadeia de suprimentos, o episódio demonstra como a ausência de controles eficazes pode resultar em apreensões, recalls, sanções administrativas e danos reputacionais de longo prazo, enquanto estruturas robustas de governança reduzem riscos e fortalecem a confiança do mercado.

Você vai compreender melhor:

• Como a falsificação de bebidas e alimentos impacta diretamente a saúde do consumidor e a segurança sanitária;

• O papel das autorizações, certificações e registros oficiais na proteção da cadeia legal de fornecimento;

• Como falhas de rastreabilidade e controle documental favorecem a circulação de produtos adulterados;

• Por que sistemas de qualidade, monitoramento contínuo e due diligence regulatória são fundamentais para a proteção das marcas;

• Como empresas, inclusive de menor porte, podem estruturar modelos eficientes de prevenção à falsificação sem comprometer sua competitividade.

Em um contexto no qual produtos falsificados podem causar intoxicações, agravos à saúde e perda de vidas, além de prejuízos econômicos expressivos, a negligência deixa de ser apenas um risco operacional e passa a representar uma ameaça institucional. A prevenção à falsificação exige cadeias de suprimento transparentes, rastreáveis e plenamente alinhadas à legislação sanitária vigente.

Acompanhe este episódio para entender como a adoção de estratégias regulatórias sólidas, aliadas a controles logísticos e sistemas de qualidade eficazes, contribui para a proteção do consumidor, a preservação das marcas e a integridade do mercado de bebidas e alimentos.

Saiba mais em: els-solutions.com

Este episódio foi gravado em 2026. Parte das informações discutidas pode ter sido atualizada posteriormente. O podcast foi elaborado com base em diversas fontes bibliográficas. As opiniões expressas refletem a experiência profissional dos membros da ELS e o conteúdo das referências consultadas.

How Efficiency in Import and Distribution Logistics Drives Global Success?

Efficient importation and distribution are no longer operational afterthoughts, they are strategic imperatives for pharmaceutical and MedTech companies seeking global expansion. But what are the hidden risks, and how can companies truly optimize their logistics while remaining compliant?

In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, explores how mastering the complexities of global import and distribution logistics is key to regulatory compliance, operational efficiency, and patient safety.

From navigating regulatory mazes to mitigating supply chain risks, we’ll break down what separates companies that scale globally from those that stumble at the border.

You’ll learn more about:

• How regulatory compliance shapes logistics strategies across multiple markets
• The key certifications that open doors to international trade
• Common challenges in customs clearance and how to overcome them
• How to prevent product recalls, supply interruptions, and reputational damage
• Why robust quality systems and traceability are essential in combatting counterfeits
• How smaller companies can scale efficiently through strategic logistics planning

In a market where a single delay can cost millions, or put lives at risk, companies cannot afford inefficiency. Supply chains must be proactive, compliant, and resilient.

Tune in now to understand how optimizing your import and distribution operations can drive faster market entry, reduce costs, and safeguard both your product and your patients.

Learn more at els-solutions.com

This episode was recorded in 2025. Some of the data discussed may have changed since then. This podcast has been prepared using various bibliographic sources. The opinions expressed reflect the professional experiences of ELS members and referenced material.

Artificial Intelligence is Reshaping Pharmacovigilance – But Are You Ready?

With over 1.5 million adverse drug reactions reported annually in the EU alone, the pressure on pharmacovigilance systems has never been greater. Could artificial intelligence (AI) be the answer?

In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, discusses how AI is transforming the landscape of drug safety, and what pharmaceutical companies must do to stay ahead.

From automation and real-time signal detection to regulatory hurdles and ethical challenges, we break down how AI is redefining the future of pharmacovigilance and what that means for compliance, patient safety, and innovation.

You’ll learn more about:

• How AI enhances adverse event detection across large, unstructured data sources

• Compliance requirements under EMA, FDA, and ISO standards

• Why early-stage integration of AI is a strategic (not optional) investment

• How companies can adopt scalable, cost-effective AI solutions without compromising compliance

The integration of AI into pharmacovigilance isn’t a distant possibility, it’s an urgent priority. But real transformation requires more than just algorithms. It demands strategic planning, regulatory alignment, and expert guidance.

Tune in now to understand how your company can use AI to enhance pharmacovigilance performance, reduce risk, and strengthen patient trust.

Learn more at els-solutions.com/This episode was recorded in 2025. Some of the data discussed may have changed since then. This podcast has been prepared using various bibliographic sources. The opinions expressed reflect the professional experiences of ELS members and referenced material.

Brazil’s medicinal cannabis market is evolving rapidly, with more patients, new regulatory pathways, and a growing industry presence.

But how accessible are these treatments, and what are the biggest challenges companies face?

In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins explores the business and regulatory landscape of medicinal cannabis in Brazil.

From market trends to future policy changes, we’ll break down what’s shaping this fast-moving sector.

You’ll learn more about:

• The surge in patient numbers and what it means for market growth
• Regulatory frameworks for cannabis-based treatments and their challenges
• Why official drug registrations remain rare despite existing pathways
• The impact of Anvisa’s upcoming regulatory agenda on the industry

With Brazil poised to become a key player in Latin America's cannabis market, understanding these developments is crucial. Tune in now to stay ahead of the curve.

Learn more at els-solutions.com.

"This episode was recorded in 2024. As such, some of the data discussed may have changed. This podcast has been prepared from different bibliographic sources. The opinions and comments conveyed therein are based on previous corporate experiences of ELS members, in addition to the references listed."

The pharmaceutical market is constantly evolving,shaped by innovation, shifting demands, and regulatory developments.

In this episode of International Pharma Talks, our host, Dr. Diogo Sousa-Martins explores how the industry is changing and what these transformations mean forthe future.

Tune in to discover:

•  How technology is reshaping drug development andhealthcare
• The impact of regulatory changes on marketstrategies
• The shift towards personalized medicine andpatient-centered care
• The role of emerging markets in the globalpharmaceutical landscape

Understanding these changes is crucial for staying ahead in the industry. Learn more about it at els-solutions.com

* "This podcast has been prepared from different bibliographic sources. As such, the opinion and comments conveyed therein are based on previous corporate experiences of ELS members, in addition to the referenceslisted." 

What does the future look like for the pharma industry in 2025?

Join Dr. Diogo Sousa-Martins in our latest episode of International Pharma Talks, where he explores the key trends shaping the pharmaceutical landscape this year. With rapid advancements in AI, regulatory changes, and the growing importance of personalized medicine, staying ahead has never been more critical.

In this episode, you’ll learn more about:

As the industry evolves, understanding these shifts will be essential for success. Tune in now to gain valuable insights and prepare for what’s ahead.

Learn more about it at els-solutions.com

In the 37th episode, our host, Dr. Diogo Sousa-Martins delves into the dynamic and rapidly evolving cannabis market in Europe, analyzing how the regulatory frameworks, market trends, and societal implications works in this controversial yet very promising industry.